Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Assets (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Assets for 10 consecutive years, with $330.4 million as the latest value for Q4 2025.

  • Quarterly Assets fell 37.38% to $330.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $330.4 million through Dec 2025, down 37.38% year-over-year, with the annual reading at $330.4 million for FY2025, 37.38% down from the prior year.
  • Assets hit $330.4 million in Q4 2025 for Rocket Pharmaceuticals, down from $368.0 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $598.8 million in Q3 2023 to a low of $330.4 million in Q4 2025.
  • Historically, Assets has averaged $480.0 million across 5 years, with a median of $484.0 million in 2021.
  • Biggest five-year swings in Assets: soared 58.05% in 2021 and later plummeted 37.38% in 2025.
  • Year by year, Assets stood at $497.0 million in 2021, then rose by 11.02% to $551.8 million in 2022, then rose by 2.63% to $566.3 million in 2023, then fell by 6.82% to $527.7 million in 2024, then crashed by 37.38% to $330.4 million in 2025.
  • Business Quant data shows Assets for RCKT at $330.4 million in Q4 2025, $368.0 million in Q3 2025, and $421.0 million in Q2 2025.